论文部分内容阅读
观察普萘洛尔（ｐｒｏｐｒａｎｏｌｏｌ）和螺内酯（Ｓｐｉｒｏｎｏｌａｃｔｏｎｅ）对肝硬化食管胃底静脉曲张破裂出血的预防作用，及对肝硬化病人生存期的影响。将病人随机分对照组及普萘洛尔、螺内酯组三组，追踪观察６月、１２月、２４月的出血率、生存率及死亡原因。结果显示：普萘洛尔及螺内酯用药后出血率均明显降低，但生存率和对照组比无明显差异，长期维持用药未见明显不良反应。提示：普萘洛尔及螺内酯对肝硬化食管胃底静脉曲张破裂出血有预防作用，而对肝硬化病人的生存期无明显影响。
To observe the propranolol (propranolol) and spironolactone (Spironolactone) on cirrhosis of esophageal varices bleeding prevention, and the impact of survival in patients with cirrhosis. Patients were randomly divided into control group and propranolol, spironolactone group three groups were followed up to observe the bleeding rate, survival rate and cause of death in June, December and 24 months. The results showed that propranolol and spironolactone significantly reduced the bleeding rate after treatment, but there was no significant difference between the two groups in the survival rate and in the control group. No obvious adverse reactions were observed after prolonged use of propranolol. Tip: Propranolol and spironolactone on cirrhosis of esophageal varices bleeding prevention, but no significant effect on the survival of patients with cirrhosis.